^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + BLU-222 (CDK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer
Published date:
12/02/2023
Excerpt:
The combination of BLU-222 plus the CDK4/6 inhibitor induced durable tumor regression and prolonged survival, which continued unabated following drug removal….These results show robust activity of BLU-222 in combination with CDK4/6 inhibitors in breast cancer cell lines and PDX models resistant to CDK4/6 inhibitors, providing a strong rationale for advancing BLU-222 plus CDK4/6 inhibitor treatment to clinical development in HRpositive/HER2-negative breast cancer patients who have progressed on CDK4/6 inhibitors.
